-
Product Insights
Fondazione Fornasini Solar PV Park
Fondazione Fornasini Solar PV Park is a solar PV project located in Emilia-Romagna, Italy. The project came online in 2022. Empower your strategies with our Fondazione Fornasini Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data...
-
Product Insights
NewUsher Syndrome – Drugs In Development, 2024
Empower your strategies with our Usher Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration; prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids, and Vitamin A supplementation. The Usher Syndrome drugs in development market research...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024
Empower your strategies with our Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease, an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision; dark, empty spots in the center of vision; and difficulty reading or performing detail work. Risk factors include arteriosclerosis,...
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Track & Monitor
Innovation in Pharmaceuticals: Viral vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Viral vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Gene therapy delivery using viral vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Gene therapy delivery using viral vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed...
-
Track & Monitor
Innovation in Pharmaceuticals: Transcription factors for AAV
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Transcription factors for AAV segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Product Insights
Essential Thrombocythemia Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Essential Thrombocythemia Global Clinical Trials Review, H2, 2017" provides an overview of Essential Thrombocythemia clinical trials scenario. This report provides top line data relating to the clinical trials on Essential Thrombocythemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Analyst Opinions
COVID-19 Impact on Aldi
Like other grocers Aldi will benefit from COVID-19 with increased demand for food globally as consumers stay at home. Aldi has taken steps to support the community across countries and these actions will boost customer perceptions of the brand, boosting sales in the long term. The Coronavirus (COVID-19) company impact report analyses how the pandemic will impact Aldi's performance.